Abstract. AB␣C, a major protein phosphatase 2A (PP2A) heterotrimeric enzyme, binds to and regulates the microtubule cytoskeleton and tau. We have shown that AB␣C protein expression levels are selectively reduced in Alzheimer disease (AD). Notably, the carboxyl methylation of PP2A catalytic subunit (PP2A C ) is critically required for AB␣C holoenzyme assembly, and catalyzed by a specific methyltransferase (PPMT). Here, we provide the first analysis of human PPMT and methylated PP2A C in brain regions from AD, non-AD demented, and aged control autopsy cases. Immunoblotting analyses revealed that PPMT protein expression and PP2A C methylation levels were quantitatively decreased in AD-affected brain regions. Immunohistochemical studies showed that PPMT was abundant in neurons throughout the cortex in normal control and non-AD demented cases. However, in AD, there was a regional loss of PPMT immunoreactivity that closely paralleled the severity of tau pathology, but not amyloid plaque burden. We propose that the deregulation of PPMT and PP2A methylation/demethylation cycles contributes to AD pathogenesis, by inducing changes in PP2A heteromultimeric composition and substrate specificity. In turn, PP2A dysfunction compromises the mechanisms that control tau, neuronal plasticity, and survival.
INTRODUCTION
Protein phosphatase 2A (PP2A) enzymes are major brain serine/threonine protein phosphatases. In vivo, PP2A enzymes predominantly exist as heterotrimers containing a catalytic subunit (C), a scaffolding subunit (A), and a regulatory subunit (B). Several distinct families of B subunits have been identified, and the formation of specific ''ABC'' heterotrimers influences PP2A catalytic activity, substrate specificity, targeting to defined intracellular domains, and recruitment to signaling complexes (1) . For instance, the holoenzyme containing the B␣ (also called B55 or PR55) subunit is a major neuronal PP2A isoform that binds to microtubules and the microtubuleassociated protein, tau (2, 3) . The regulation of PP2A subunit assembly and activity is remarkably complex. The highly conserved carboxy-terminal sequence of the C subunit (PP2A C ) can undergo post-translational modifications, including phosphorylation and carboxyl methylation. PP2A C phosphorylation transiently inactivates PP2A (4) . Methylation of PP2A C on the Leu-309 residue critically modulates the binding of regulatory B subunits to the (AC) core enzyme, thereby affecting PP2A substrate specificity, targeting, and cellular functions (5) (6) (7) (8) (9) (10) (11) . Of particular interest is the finding that methylation-defective PP2A C mutants lose their ability to associate with the regulatory B␣ subunit (5) (6) (7) (8) (9) (10) (11) . Thus, the reversible methylation of PP2A C plays a crucial role in modulating holoenzyme assembly. It is catalyzed in mammalian cells by a specific Leu carboxyl methyltransferase (PPMT) (9, (12) (13) (14) , whereas the methyl group is removed by a methylesterase (15) (16) (17) . PPMT activity depends on S-Adenosylmethionine (SAM or AdoMet) (18, 19) , a key regulator of metabolic pathways (20) .
Chief neuropathological hallmarks of Alzheimer disease (AD) are the accumulation of neurofibrillary tangles (NFTs) and amyloid-␤ (〈␤)-containing senile plaques (SPs) in the neocortex and hippocampus. Both NFTs and the peripheral neurites found in neuritic-type SPs consist, at the ultrastructural level, of aggregates of paired helical filaments (PHFs) containing hyperphosphorylated tau proteins. Significantly, specific inhibition of PP2A alone is sufficient to induce PHF-like tau hyperphosphorylation in cultured cells (3) and in mice (21) . Moreover, the selective PP1/PP2A inhibitor, okadaic acid, not only induces tau hyperphosphorylation, but also A␤ deposition, alterations in synaptic plasticity, neurodegeneration, and memory impairment in vivo (22) (23) (24) (25) (26) . Interestingly, microarray analyses have revealed that expression of the PP2A C gene is downregulated in early AD (27) . It has also been reported that PP2A C␣, B55␥, and PR61 subunit mRNA levels are reduced in AD hippocampus (28) . In contrast, Zhao et al have recently shown that PP2A mRNA expression levels were increased, while PP2A protein expression and enzymatic functions were defective in AD fibroblasts (29) . These authors suggested that increased basal levels of PP2A mRNA in AD fibroblasts reflect a cellular compensatory mechanism for PP2A reduced expression that may be active in those living cells, but obliterated in AD terminal states. In agreement with the results from Zhao et al showing reduced PP2A protein expression levels in AD fibroblasts, we have recently reported that AB␣C protein expression levels are selectively reduced in AD-affected brain regions (30) . Because AB␣C is a major tau phosphatase, its reduced expression likely contributes to the decreased neuronal PP2A activity known to take place in AD-affected brain regions (30, 31) , thereby promoting the accumulation of hyperphosphorylated PHF-tau (3, 32) . Although there is growing evidence that PP2A deregulation may play a pivotal role in AD pathogenesis, the mechanisms underlying its dysfunction in this disorder remain to be elucidated.
Despite their fundamental importance in PP2A regulation, nothing is currently known about the properties, modulation, and function of PPMT and PP2A methylation in human brain. Interestingly, SAM levels are reduced in AD-affected patients (33) , suggesting that SAMdependent enzymes like PPMT could become deregulated in this disorder. Based on those observations, we decided to compare PP2A C methylation status and PPMT distribution and expression levels in a large series of AD and control autopsy cases. Combined immunohistochemical and Western blot analyses of brain tissue were used to test the hypothesis that alterations in PPMT and PP2A methylation preferentially occur in AD and contribute to PP2A deregulation in this disorder.
MATERIALS AND METHODS

Human Brain Tissue
Fully-characterized brain tissue was obtained through the Alzheimer Disease Center (ADC) Neuropathology Core Brain Bank at the University of Texas Southwestern Medical Center, as described previously (30) . Each brain was processed and diagnosed according to the ADC Neuropathology Core protocol using standard methods. The diagnosis of AD was established according to CERAD criteria (34, 35) , using formalin fixed, thioflavine-S-stained paraffin sections of hippocampus and neocortex. The fixation time of brain tissue was variable, but was a minimum of 2 weeks for all cases. Fresh samples were also taken on all cases from the middle frontal gyrus (Brodmann areas 9 or 46), superior temporal gyrus (Brodmann area 22) , and the cerebellar hemisphere, immediately adjacent to the slabs fixed in formalin for histopathology. The samples were snap-frozen in liquid nitrogen, and stored at Ϫ70ЊC until use. The general characteristics of the cases analyzed here are summarized in Table 1 .
Western Blot Analysis of Human Brain Samples
Because the neuropathology in AD is characterized by extensive neuronal cell loss in affected areas, protein expression levels were compared in defined brain tissue samples that had been carefully normalized by homogenization at a fixed ratio (tissue weight/buffer volume) (30) . The brain tissue samples were thawed and homogenized at a constant ratio of 1 g of tissue per 10 ml of buffer (Tris 10 mM, 150 mM NaCl, 2 mM EGTA, 2 mM dithiothreitol, pH 7.4), containing a cocktail of protease inhibitors (Complete mini , Roche, Indianapolis, IN). Importantly, for these studies, okadaic acid (LC Laboratories, Woburn, MA; 2 M) and PMSF (Sigma-Aldrich, St. Louis, MO; 5 mM) were added to the buffer in order to block the activities of PP2A methylesterases (15, 17, (36) (37) (38) . After homogenization, samples were briefly sonicated and centrifuged for 5 min at 14,000 g to remove any remaining insoluble material. They were immediately analyzed for PP2A methylation. Remaining aliquots containing glycerol (10% v/v) were stored at Ϫ80ЊC.
Equivalent aliquots of brain homogenates were resolved by SDS-PAGE on 12% polyacrylamide gels (Amersham Biosciences, Piscataway, NJ), followed by immunoblotting with the antibodies described in Table 2 . Immunoreactive proteins were detected using SuperSignal Chemiluminescence substrates (Pierce, Rockford, IL). Blotting with anti-actin antibodies was used as a control for protein loading. The total levels of PP2A C (methylated plus demethylated forms) were determined by probing the immunoblots with a monoclonal anti-C antibody.
In some experiments, methylated PP2A C levels were directly analyzed using the methylation-specific, monoclonal 2A10 antibody. Previous studies have shown that alkali-induced demethylation of PP2A C results in changes in PP2A C electrophoretic mobility and enhanced immunoreactivity of PP2A C to antibodies directed against the C-terminus peptide of PP2A. This property has been widely used to monitor PP2A C methylation status (6, 36) . Thus, in order to analyze demethylated PP2A C levels, equivalent aliquots of brain homogenates (10 l) were incubated for 30 min at 37ЊC in the absence or presence of 0.1 M NaOH. As described previously (36, 38) , this alkaline treatment resulted in demethylation of PP2A C at Leu-309 and unmasking of the epitope recognized by a polyclonal antibody directed against the carboxy-terminal 299-309 region of PP2A C . Because total PP2A C expression levels are slightly decreased in AD versus controls (30) , the levels of demethylated and methylated PP2A C were quantitated after densitometry scanning of the immunoblots using Kodak Image software (Eastman Kodak Company, Rochester, NY), by comparing the immunoreactivity of equivalent NaOH-treated and untreated brain aliquots to the methylation-sensitive antibodies. Several exposures of the same blots were assessed for quantification to ensure that the signals that were analyzed were within the linear range.
Statistical Analysis
The data are presented as mean values Ϯ SD, and were analyzed using the Student t-test. Differences with p values Ͻ 0.05 were considered statistically significant.
Immunohistochemistry
Immunohistochemical procedures were performed in the UT Southwestern Pathology Immunohistochemistry Laboratory, exactly as described previously (30) . Briefly, paraffin sections (3 m thick) from normal or diseased human formalin-fixed brain cortices were immunostained at room temperature on a BioTek Solutions TechMate 1000 automated immunostainer Aged control cases (''CONTROL'') included cases without (''NORMAL''; 7 cases; Braak stage 0) or with (''ARND''; 17 cases; Braak stage I-IV) evidence of age-related neurofibrillary degeneration. All ''AD'' cases (Braak stage III-VI) met CERAD neuropathological criteria for probable or definite AD. All 7 NORMAL, 17 ARND, and 48 AD cases with comparable postmortem interval (PMI) values were analyzed by Western blotting for PP2A c and PPMT expression. A representative subset (5 NORMAL, 5 ARND, and 12 AD) of those cases was used for the analyses of PPMT distribution by immunohistochemistry. Note that cases with a complete range of NFT and SP density (none, sparse, moderate or frequent; according to CERAD criteria) were analyzed in our immunoblotting and immunohistochemical studies. 5 non-AD cases, comprising vascular dementia (''VD''), diffuse Lewy body disease (''DLBD''), and frontotemporal dementia with ubiquitinated inclusions (''FTD-Ub''), were only analyzed by immunohistochemistry due to the lack of availability of frozen tissue. (Ventana Medical Systems, Tucson, AZ), using heat-induced epitope retrieval techniques in order to enhance epitope antigenicity to maximal levels, and neutralize potential effects of variable fixation time among cases (39) . All sections were treated with formic acid to enhance antigenicity of tangles by tau immunostaining (40) . Labeling was performed using the UltraStreptavidin secondary detection kit for horseradish peroxidase (HRP)/diaminobenzidine (DAB) staining (Signet Laboratories Inc., Dedham, MA), and the ChemMate secondary detection kit for alkaline phosphatase/BT red staining (Ventana Medical Systems). A known positive control section was included in each run to assure proper staining. Adjacent sections stained with pre-immune sera were used as negative controls to ensure the specificity of the staining. Sections were counterstained with hematoxylin, and photographed on a Nikon Optiphot-2 microscope fitted with a DXM1200F digital camera (Nikon Instruments, Melville, NY). Positive reactions with DAB were identified as dark brown reaction product. Positive reactions with BT Red were identified as red reaction product.
RESULTS
Downregulation of PP2A Methylation and PPMT Protein Expression Levels in AD-Affected Brain Regions
We first compared methylated PP2A C levels in brain homogenates from a series of neuropathologically confirmed autopsy cases of AD (''AD'') and aged controls. Control cases included cases without (''NORMAL'') or 2 . Quantification of methylated PP2A C levels in frontal, temporal, and cerebellar extracts from control and AD cases. Homogenates were prepared from the frontal cortex, temporal lobe, and cerebellum of all control and AD cases described in Table 1 . Equivalent aliquots (10 l) were treated with or without NaOH, and analyzed by Western blotting with methylation-sensitive anti-PP2A C antibodies, as described in Material and Methods. A: Representative blots from 4 NOR-MAL control (lanes 1-4) and 4 AD (lanes 5-8) cases analyzed for demethylated PP2A C using anti-C 299/309 antibody. B-D: Quantitative analysis of methylated PP2A C levels in frontal (B), temporal (C), and cerebellar (D) homogenates from NORMAL, ARND, and AD cases. Results are expressed as percent of the relative methylated PP2A C levels measured in NORMAL controls, and are the mean Ϯ SD of determinations performed in all 24 control and 48 AD cases described in Table 1 (*p Ͻ 0.05; **p Ͻ 0.001; t-test). Note that relative to controls, methylated PP2A C levels are significantly decreased in AD frontal/ temporal cortex, but not in the cerebellum.
with (''ARND'') histological evidence of age-related neurofibrillary degeneration (Table 1) . In preliminary studies, we examined a large series of frozen autopsy brain tissue with a wide range of postmortem interval (PMI) values, to determine whether high PMI values detrimentally affect PP2A C methylation status. We were unable to find any statistically significant correlation between PMI values of our tissue samples and PP2A C methylated levels, either within control or AD series (data not shown). On the other hand, homogenization with an adequate buffer and prompt processing of the brain tissue samples were found to be critical for preventing rapid PP2A C demethylation. In any case, brain tissue with relatively short PMI was preferentially chosen in the present study (Table 1) , since the loss of PP2A activity is minimized in human postmortem tissue under such conditions (31).
Western blot analysis of frontal cortex homogenates was performed with antibodies recognizing either the methylated, demethylated, or both forms of PP2A C (Fig.  1) . As observed in a previous study (30) , total PP2A C expression levels were slightly decreased in AD versus control brain samples. The utilization of methylation-sensitive antibodies further suggested that PP2A C was more demethylated in frontal cortex homogenates from AD, relative to controls. When comparing in parallel homogenates from 3 distinct brain regions of additional cases (Fig. 2) , it became more apparent that the relative amounts of methylated PP2A C were reduced in AD frontal and temporal, but not cerebellar extracts, compared to controls. The quantitative analysis of immunoblots of all 72 cases examined in this study (Table 1) 
-test).
Note that relative to controls, PPMT protein expression levels are reduced by approximately half in AD frontal/temporal cortex, but not in the cerebellum. but reduced by approximately half in AD (p Ͻ 0.001), relative to NORMAL cases. In contrast, they were not statistically different in NORMAL, ARND (p Ͼ 0.5), or AD (p Ͼ 0.5) homogenates of the cerebellum, a brain region acknowledged to be less susceptible to AD lesions. Thus, a reduction in overall PP2A C methylation occurred preferentially in AD-affected regions.
Because PPMT methylates PP2A C , we next assessed whether its expression was altered in AD. The same brain aliquots that were used for quantitating PP2A C methylation were re-analyzed for PPMT expression (Fig. 3) . In preliminary experiments, a polyclonal antibody raised against mouse PPMT was tested by immunoblotting and found to specifically recognize a single band corresponding to human PPMT in our brain extracts. No signal was observed with the corresponding pre-immune serum (not shown). PPMT immunoreactivity in the frontal cortex appeared to be significantly reduced in AD, relative to controls. Interestingly, a similar decrease in the relative signal for PP2A B␣ subunit was clearly visible in AD, versus control lanes, when the same blot was reprobed with monoclonal anti-PP2A B␣ subunit antibodies. Immunostaining with anti-actin antibodies further indicated that changes in PPMT immunoreactivity in AD were specific, and did not result from overall protein loss in those brain samples. Careful quantitative analysis of immunoblots performed with all cases confirmed that PPMT expression was somewhat reduced in ARND (p Ͻ 0.001), and significantly decreased in AD-affected frontal and temporal regions (p Ͻ 0.001), relative to NORMAL cases. However, PPMT amounts were not reduced in the cerebellum of either ARND (p Ͼ 0.05) or AD (p Ͼ 0.05), relative to NORMAL cases.
PPMT Distribution in Normal Human Brain
Immunoblotting analyses can reveal global and quantitative changes in the expression of a particular protein, but they fail to give detailed information on whether those changes occur in selective brain sub-areas or cell types. We thus decided to compare by immunohistochemistry the distribution of methylated PP2A C and PPMT in a representative subset of the control and AD cases that we had studied by Western blotting. We have previously successfully studied PP2A C distribution in human brain using methylation-insensitive antibodies against PP2A C (30) . Unfortunately, we were unable to specifically assess the distribution of methylated PP2A C by immunohistochemistry using anti-PP2A C ''2A10'' antibodies, because of poor immunoreactivity of this monoclonal antibody in fixed human tissue (not shown). We thus concentrated our effort on PPMT. PPMT distribution was first investigated in several brain regions of a NORMAL case (Fig. 4) . As observed previously with anti-PP2A A, B␣ and C subunit antibodies (30) , neuronal cell bodies and processes were strongly immunoreactive with anti-PPMT antibodies throughout the human brain cortex. Diffuse neuropil staining likely representing the widespread distribution and abundance of PPMT in neuronal processes was prevalent throughout the sections. A similar phenomenon has already been noted in earlier immunohistochemical studies performed with PP2A anti-subunit antibodies (30) . In contrast to the strong neuronal staining, extremely weak, granular, glial immunoreactivity was seldom observed.
Altered PPMT Distribution in AD
It is agreed by most investigators that PHF accumulation, if not central to neuronal dysfunction and death in AD, is at least a useful marker for populations of neurons and brain regions at risk to degenerate in that disorder. Thus, double labeling with PHF-1, an antibody specifically recognizing hyperphosphorylated PHF-tau (41), was used to determine whether the cellular localization of PPMT was altered in regions of severe AD pathology, i.e. the frontal/temporal cortices and the hippocampus. As illustrated in Figure 5 , strong neuronal perikaryal and neuropil PPMT immunoreactivity, similar to that of NORMAL cases, was observed in ARND frontal cortex. In contrast to ARND, there was a significant overall reduction of perikaryal PPMT immunoreactivity in AD cases that had been stained in parallel. Single and double labeling experiments pointed to a progressive and marked decrease of PPMT staining intensity that appeared to correlate with increasing frequency of PHF-1-positive lesions. Noticeably, there was a concomitant reduction of PPMT neuropil staining in AD cases, probably as a result of the loss of neuronal processes in this disease. Despite its overall reduced immunostaining intensity in AD, PPMT could be clearly detected in neurons that bore nascent tangles. However, PHF-1-positive dystrophic neurites and neurons completely filled with PHF-tau material showed very little, if any, immunoreactivity with anti-PPMT antibodies. A similar PPMT/PHF-tau immunostaining pattern emerged when sections from the hippocampus were examined (Fig. 6 ). In the NORMAL case, neuronal PPMT immunoreactivity was very pronounced in the hippocampal CA1 and CA2 regions, which expectedly were not immunoreactive with PHF-1 antibodies. In AD, however, these regions were much less intensely stained by anti-PPMT antibodies. The loss of PPMT immunoreactivity was especially prominent in the CA1 region, which is more vulnerable to the formation of PHF-tau-rich lesions than the CA2 area, as confirmed by immunostaining with PHF-1 antibodies. The amount of PPMT immunoreactivity was considerably reduced in tangle-bearing neurons that were prevalent in the CA-1 region. We have previously reported that neuronal B␣ subunit expression levels are significantly reduced in ADaffected regions (30) . Indeed, labeling of adjacent sections of the same cases with PHF-1 and anti-B␣ antibodies clearly showed that both PPMT and PP2A holoenzymes containing the B␣ subunit shared similar neuronal distribution patterns in control and AD cases. Although immunohistochemical studies are not considered quantitative per se, these results strongly suggest that the regional loss of PPMT immunoreactivity in AD closely parallels the severity of phosphorylated tau pathology and reflects the loss of PPMT expression in both neuronal perikarya and neuropil. This overall reduction in PPMT immunoreactivity is in agreement with the results from our immunoblotting studies performed on frozen tissue of representative regions obtained from the same cases.
Next, double labeling of brain sections with anti-PPMT and anti-A␤ antibodies was carried out to compare the distribution of PPMT and A␤-containing SPs (Fig. 7) . Double labeling with anti-PPMT and PHF-1 antibodies was performed on adjacent sections to allow the distinction between diffuse SPs, which are PHF-1-negative and commonly observed in aged patients, and the PHF-1-positive neuritic-type SPs that are characteristic of AD pathology. Strong perikaryal and neuropil PPMT immunoreactivity was present throughout the double-labeled ARND frontal cortex, within and around the A␤ deposits of diffuse plaques present in this case. Not surprisingly, the overall intensity of the PPMT signal was diminished in AD frontal cortex. However, the neuronal PPMT immunostaining pattern did not appear to be particularly influenced by the overwhelming presence of a large number of diffuse and neuritic-type SPs in this AD-affected region. In fact, PPMT immunoreactivity was also observed within neuritic-type SPs and in surrounding neurons. Careful examination of additional AD cases with a wide range of SP severity further confirmed the absence of obvious correlation between qualitative PPMT neuronal staining and amyloid plaque burden (not shown). This is in striking contrast with the inverse relationship between PPMT immunoreactivity and tangle/neurite load that we qualitatively identified in adjacent sections from the same cases.
PPMT Distribution Is Not Altered in Non-AD Dementias without Phosphorylated Tau Pathology
Because altered PPMT expression could also result from general neurodegenerative processes that are not exclusive to AD pathology, we also investigated its distribution in selected non-AD dementia cases (Fig. 8) , comprising vascular dementia (VD), diffuse Lewy body disease (DLBD), and frontotemporal dementia with ubiquitinated inclusions (FTD-Ub) (42) . The absence of phosphorylated tau pathology in these particular cases was confirmed by the lack of immunoreactivity to PHF-1 antibodies. In addition, the pattern and intensity of PPMT immunostaining in these disorders was indistinguishable from that observed in double-labeled NOR-MAL control cortical sections. Together, these observations suggest that the selective loss of neuronal PPMT immunoreactivity in AD-affected regions does not simply result from random neurodegenerative events, but is rather a reflection of more specific pathological processes.
DISCUSSION
We show here for the first time that methylated PP2A C levels are reduced in AD frontal/temporal cortex, relative to controls. It has previously been reported that, in porcine and bovine brain tissue, all methylated PP2A C is found associated with PP2A heterotrimeric enzymes, whereas the dimeric (AC) form of PP2A recovered in the brain extracts is fully demethylated (8, 13) . Thus, changes in PP2A C methylation levels likely influence the proportion of PP2A dimers and heterotrimers in vivo. Interestingly, we have recently observed that there was a significant loss of B␣ subunit expression in AD-affected regions (30) . Because the B␣ subunit is not stable as a monomer and is always associated with the (AC) core enzyme (43), a loss of B␣ translates into a net loss of AB␣C heterotrimers. In apparent conflict with our results indicating reduced amounts of AB␣C in AD, it has been previously reported that B␣ mRNA levels in the hippocampus are similar in AD and control cases (28) . Yet, there is no obligate linear correlation between mRNA and protein expression levels in vivo. Indeed, a variety of events, such as post-transcriptional regulation of protein synthesis, folding, stability, and degradation critically modulate the levels of intracellular protein pools in vivo. Thus, we propose that changes in B␣ expression levels in AD occur at the posttranslational level. Because the B␣ subunit cannot stably associate with demethylated PP2A, decreased PP2A C methylation in AD precludes the formation of stable B␣-containing heterotrimers and may explain, at least in part, the overall loss of AB␣C holoenzymes in this disorder. Conversely, it could be argued that reduced methylated PP2A C levels directly reflect the overall loss of methylated AB␣C heterotrimers in AD cortex. However, our observation that PPMT levels are also selectively decreased in AD-affected regions and in tangle-bearing neurons, but not in 3 other non-AD dementias without phosphorylated tau pathology, rather favors the hypothesis that PP2A becomes deregulated during the disease process. Notably, the expression levels of PPMT, methylated PP2A C and B␣ were reduced by approximately half in the same AD brain extracts. Because of this striking correlation, we favor a model (Fig. 9) wherein the loss of PPMT in AD directly impairs PP2A C methylation, which in turn affects PP2A holoenzyme assembly. The resulting changes in endogenous PP2A subunit composition then severely affect PP2A targeting, substrate specificity, and activity.
What are the physiological consequences of deregulating PP2A methylation? It has been reported that methylation-defective PP2A C mutants, which are unable to associate with the B␣ subunit, enhance the sensitivity of yeast cells to microtubule destabilization, and reduce cell viability (7) . Based on the conserved role of AB␣C in the regulation of microtubules in yeast and mammalian cells (1) , it is likely that altered PP2A methylation in AD neurons could generate defects in the microtubule cytoskeletal architecture. In addition, we have shown that the binding to and dephosphorylation of tau by PP2A is B subunit-specific (3). The inability of demethylated PP2A C to associate with B␣ is therefore of particular importance. Inhibition of AB␣C induces PHF-like tau phosphorylation (3). Conversely, PHF-like phosphorylation of tau inhibits its binding to AB␣C (32, 44) , so that reduced AB␣C levels in AD can theoretically contribute to the accumulation of hyperphosphorylated tau. In support of this hypothesis, we noticed that the regional loss of PPMT/AB␣C immunoreactivity in AD closely parallels PPMT is a SAM-dependent enzyme that methylates PP2A C , which is critically required for assembly of active AB␣C heterotrimers. Based on our results, decreased neuronal PPMT expression levels in AD may compromise PP2A C methylation, which in turn would result in changes in PP2A subunit composition and substrate specificity, and a net loss of AB␣C holoenzymes. Because AB␣C binds to, dephosphorylates, and regulates the functions of both tau and microtubules, decreased AB␣C expression would lead to accumulation of hyperphosphorylated tau and alterations in neuronal cytoskeletal functions. Other PP2A-dependent signaling pathways that regulate cell cycle, growth and survival could also become deregulated. Notably, it has been reported that SAM-dependent homocysteine metabolic pathways are deregulated in AD-affected patients. Such alterations could further exacerbate the harmful effects of PPMT downregulation in AD. Additional factors (e.g. brain insults or genetic factors) could also contribute to PP2A dysfunction in AD.
the severity of phosphorylated tau pathology in AD. Interestingly, the presence of NFTs and neuron loss correlate with the progression of cognitive defects in AD (45) .
Lastly, our results raise the question of what is (are) the underlying physiological cause(s) for reduced PPMT and methylated PP2A C levels in AD. It is possible that the presence of NFTs could decrease the neuronal capacity to synthesize specific gene products like PPMT, or that mutations in the PPMT gene could be present in AD patients. Moreover, it has been proposed that cerebral ischemia may be a risk factor for AD (46) . Interestingly, following ischemic damage, PP2A C becomes demethylated in specific vulnerable rat brain regions (47) , suggesting that PP2A methylation/demethylation reactions play a critical role in the regional neuronal response to brain insults. Yet, since neuronal PPMT levels were not significantly reduced in VD, additional causes may contribute to PPMT downregulation in AD-affected neurons. Remarkably, PPMT activity is S-Adenosylmethionine (SAM or AdoMet)-dependent (18) , and the levels of SAM, an essential component of the key cellular pathway that controls transmethylation and polyamine biosynthesis, are reduced in AD (33) . Alterations in the SAMdependent cycle correlate with plasma accumulation of homocysteine in AD-affected patients, and may result from dietary deficiencies in genetically predisposed individuals (48) . Recent evidence indicates that genetic enzymatic alterations of homocysteine metabolic pathways may indeed be an important risk factor in AD pathogenesis (49) . It has been hypothesized that deregulation of SAM-controlled metabolic pathways in AD-affected patients may directly contribute to PPMT inhibition (18, 50) . It is conceivable that the downregulation of PPMT that we observe in AD-affected brain regions indirectly results from its inactivation by such metabolic changes. In any case, PPMT dysfunction is likely to be aggravated by alterations in SAM metabolism and may be an important contributor to AD pathogenesis. We are currently examining whether deregulation of PPMT also occurs in other non-AD tauopathies.
